1. Scrip
  2. >>Business
  3. >>Deals

Podcast: What Does The Pfizer/Seagen Merger Mean For M&A In 2023?

A Discussion Of Current Deal Trends

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Scrip overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and its ramifications for the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.

M&A
Will the Pfizer/Seagen deal mean a wave of larger M&A in biopharma? • Source: Shutterstock

Pfizer Inc.’s $43bn offer to buy Seagen Inc. in March was the biggest biopharmaceutical merger-and-acquisition deal since 2019. With 2022 having yielded the lowest amount of biopharma M&A by dollar value in several years, Scrip’s Joseph Haas discussed the Pfizer/Seagen deal, biopharma deal-making in 2022 and where it may be headed in 2023 with Mike King, managing director and head of healthcare research at EF Hutton Group, and Matt Gardella, an attorney focused on biopharma deal-making at US law firm Mintz.

[Sidebar#SC148231]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.